myNEO Therapeutics has won Deloitte’s 2022 Most Disruptive Innovator award. This award, which is part of the Rising Star category of the Deloitte Technology Fast 50 competition, recognizes a promising company that has been active in the technology sector for less than four years for its revolutionary product or concept. The announcement was made at the Technology Fast 50 Awards Ceremony on 27 October 2022.

“We are proud to have won Deloitte’s 2022 Most Disruptive Innovator award. It’s exciting to be recognized for developing the most revolutionary service in this year’s Rising Star competition.”

About the Deloitte Technology Fast 50
The Technology Fast 50 competition is an annual selection of the 50 fastest growing and innovative technology companies headquartered and founded in Belgium. Public or private companies that develop a technology-related product or service and have experienced substantial revenue growth over the last four years can enter the competition for their chance to be nominated as one of the 50 fastest-growing technology companies in Belgium.

Companies that have been active in the technology sector for less than four years can participate in the special Rising Star category of the competition. These companies are judged by an independent jury on their turnover potential and scalability.

Participating in the Technology Fast 50 competition can help companies to develop their business by increasing their visibility and giving them access to Fast 50’s unique network of highly successful executives.